Cite
MLA Citation
Shipra Gandhi et al.. “321 Phase I clinical trial assessing the combination of systemic chemokine modulatory regimen targeting TLR3 with neoadjuvant chemotherapy in triple negative breast cancer.” Journal for immunotherapy of cancer, vol. 8, n.d., p. A347. http://access.bl.uk/ark:/81055/vdc_100144712771.0x000002